|
Press Releases |
|
 |
|
Friday, October 3, 2025 |
|
Eisai Highlights Breadth of Oncology Research at ESMO 2025 |
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the presentation of clinical research across its oncology portfolio and pipeline during the European Society for Medical Oncology (ESMO) Congress 2025, which is taking place in Berlin, Germany from October 17 to 21. more info >> |
|
Monday, September 29, 2025 |
|
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in China |
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that humanized anti- soluble aggregated amyloid-beta (Abeta) monoclonal antibody "LEQEMBI(R)" (generic name: lecanemab) has been approved for once every four weeks intravenous (IV) maintenance dosing by the National Medical Products Administration (NMPA) in China. more info >> |
|
Wednesday, September 24, 2025 |
|
LEQEMBI(R) (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Australia |
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the Therapeutic Goods Administration (TGA) of Australia has approved the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody "LEQEMBI(R)" (brand name, generic name: lecanemab) for mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease (AD) (collectively referred to as early AD) in adults who are either ApoEε4* non-carriers or heterozygous carriers. more info >> |
|
Wednesday, September 17, 2025 |
|
Anti-MTBR (microtubule binding region) Tau Antibody Etalanetug Granted FDA Fast Track Designation |
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that etalanetug (development code: E2814), an investigational anti-MTBR (microtubule binding region) tau antibody, was granted Fast Track designation by the U.S. Food and Drug Administration (FDA). more info >> |
|
Friday, September 12, 2025 |
|
"New Answers to Dementia" Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month |
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the release of a concept movie and new content on the dedicated website for its "New Answers to Dementia" campaign, designed to increase corporate awareness. more info >> |
|
Monday, September 8, 2025 |
|
Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025 |
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the results from a Phase Ib clinical trial (NCT06462404) of its in-house developed novel selective orexin 2 receptor agonist E2086 have been presented at the World Sleep 2025 congress, held in Singapore from September 5 to 10. more info >> |
|
Thursday, September 4, 2025 |
|
Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025 |
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the company will deliver a total of 11 presentations, including clinical data on the selective orexin 2 receptor agonist (OX2R) E2086 and the latest findings on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO(R)) at the World Sleep Congress (World Sleep 2025) to be held in Singapore from September 5 to 10. more info >> |
|
Wednesday, September 3, 2025 |
|
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status |
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that Eisai has initiated the rolling submission of the Supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (U.S. brand name: LEQEMBI(R)) subcutaneous autoinjector (SC-AI), LEQEMBI IQLIK, as a weekly starting dose after the FDA granted Fast Track Status. more info >> |
|
Monday, September 1, 2025 |
|
FDA Approves LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease |
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for once weekly lecanemab-irmb subcutaneous injection (U.S. brand name: LEQEMBI(R) IQLIKTM, pronounced "I Click") for maintenance dosing. more info >> |
|
Friday, August 29, 2025 |
|
Ministry Of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Anticancer Agent Tazemetostat for Unresectable INI1-Negative Epithelioid Sarcoma |
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has received orphan drug designation for anticancer agent the EZH2*1 inhibitor tazemetostat hydrobromide (genericname, product name "Tazverik(R) Tablets 200 mg", "tazemetostat") for unresectable INI1*2-negative epithelioid sarcoma that has progressed after chemotherapy, from the Ministry of Health, Labour and Welfare (MHLW). more info >> |
|
|
|
|
|
|
|
|
 |
Latest Press Releases |
 |
NEC Security to Provide Cybersecurity Services for GREENxEXPO 2027 (International Horticultural Expo 2027,Yokohama, Japan)
Oct 3, 2025 23:01 JST
|
|
|
Honda Announces New Investment in Motorcycle Plant in Brazil
Oct 3, 2025 22:36 JST
|
|
|
uSmart Securities Initiates Coverage on Sunrise New Energy (EPOW.US) with a "Recommended" Rating and $10.07 Price Target
Oct 3, 2025 21:30 HKT/SGT
|
|
|
Mitsubishi Heavy Industries Thermal Systems Has Launched "ETI-W"
Oct 3, 2025 22:15 JST
|
|
|
VirPoint.com Unveils 2023 Financial Results and Launches AI Trading Suite at London Investor Summit
Oct 3, 2025 21:00 HKT/SGT
|
|
|
Fujitsu expands strategic collaboration with NVIDIA to deliver full-stack AI infrastructure
Oct 3, 2025 21:24 JST
|
|
|
3D printed homes to unlock affordable living thanks to Japan-Queensland deal
Oct 3, 2025 19:00 HKT/SGT
|
|
|
Nomad eSIM x beIN SPORTS: Connecting Fans during Race Weekend
Oct 3, 2025 17:40 HKT/SGT
|
|
|
MHI Starts a Study on Optimizing the Decarbonization Value Chain Using Green Hydrogen and Ammonia Exported from India
Oct 3, 2025 18:34 JST
|
|
|
Eisai Highlights Breadth of Oncology Research at ESMO 2025
Oct 3, 2025 18:01 JST
|
|
|
Mazda Ranked Highest in J.D. Power 2025 Japan Sales Satisfaction Index Study for Second Consecutive Year in Mass Market Domestic Brands Segment
Oct 3, 2025 17:38 JST
|
|
|
MHI and QST Complete the First Outer Vertical Target of the Divertor for the ITER Project in Southern France
Oct 3, 2025 16:57 JST
|
|
|
MHI Signs Memorandum of Agreement with University of the Philippines to Consider Decarbonization Strategies in the Philippines
Oct 3, 2025 16:30 JST
|
|
|
Transnusa Launches Maiden Flight From Manado to Shenzhen
Oct 3, 2025 09:32 HKT/SGT
|
|
|
Sharp and ESI Asia Pacific partner to pioneer zinc-air flow battery technology in Queensland, Australia
Oct 3, 2025 08:00 HKT/SGT
|
|
|
|
More Press release >> |
|
|
 |
 |
 |
|
|